{"organizations": [], "uuid": "fbcaa2e5423792ff9785e73fac92bf803f0939c7", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180209.html", "section_title": "Archive News &amp; Video for Friday, 09 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-novo-nordisk-says-diabetes-drug-oz/brief-novo-nordisk-says-diabetes-drug-ozempic-has-been-approved-in-the-eu-idUSFWN1PZ0XQ", "country": "US", "domain_rank": 408, "title": "BRIEF-Novo Nordisk Says Diabetes Drug Ozempic Has Been Approved In The EU", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.454, "site_type": "news", "published": "2018-02-09T19:42:00.000+02:00", "replies_count": 0, "uuid": "fbcaa2e5423792ff9785e73fac92bf803f0939c7"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-novo-nordisk-says-diabetes-drug-oz/brief-novo-nordisk-says-diabetes-drug-ozempic-has-been-approved-in-the-eu-idUSFWN1PZ0XQ", "ord_in_thread": 0, "title": "BRIEF-Novo Nordisk Says Diabetes Drug Ozempic Has Been Approved In The EU", "locations": [], "entities": {"persons": [{"name": "stine jacobsen", "sentiment": "none"}], "locations": [{"name": "eu", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "eu", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "novo nordisk", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "novo", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 9 (Reuters) - NOVO NORDISK:\n* OZEMPIC (SEMAGLUTIDE) APPROVED IN EU FOR TREATMENT OF TYPE 2 DIABETES​\n* SAYS ‍OZEMPIC HAS BEEN APPROVED IN EU FOR USE IN A MULTI-DOSE PEN, HOWEVER, NOVO INTENDS TO SUBMIT A VARIATION APPLICATION TO EUROPEAN MEDICINES AGENCY (EMA) SEEKING APPROVAL OF AN UPDATED OZEMPIC PEN OFFERING\n* OZEMPIC WAS APPROVED BY THE U.S. FDA ON 5 DECEMBER 2017 SOURCE TEXT FOR EIKON: FURTHER COMPANY COVERAGE: (Reporting by Stine Jacobsen)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-09T19:42:00.000+02:00", "crawled": "2018-02-10T14:15:24.010+02:00", "highlightTitle": ""}